Family Medicine Doctors in Magee, MS Accepting Medicare
7 Family Medicine doctors found. Showing 1 - 7
 Thomas Rayford Blackledge Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 Third St Sw, Magee, MS 39111 Phone: 601-849-1918 |
Dr. Patrick J. Pasco, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 360 Simpson Highway 149, Suite 380, Magee, MS 39111 Phone: 601-849-1215 Fax: 601-849-5320 |
Frank C Wade Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 360 Simpson Highway 149, Suite 370, Magee, MS 39111 Phone: 601-849-1530 Fax: 601-849-1535 |
Dr. Charles Pruitt, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 360 Simpson Highway 149, Suite300, Magee, MS 39111 Phone: 601-849-1230 Fax: 601-849-1890 |
Gene David Cathey, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 360 Simpson Highway 149, Suite 360, Magee, MS 39111 Phone: 601-849-1245 |
Dr. Rudolph S Runnels Sr., M.D. Family Medicine - Sleep Medicine Medicare: Medicare Enrolled Practice Location: 360 Simpson Highway 149 Ste 170, Magee, MS 39111 Phone: 601-849-9182 Fax: 601-849-5781 |
James Shelby Presgraves, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 360 Simpson Highway 149 Ste 150, Magee, MS 39111 Phone: 601-264-6000 Fax: 601-579-5240 |
News Archive
Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation
Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients.
HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers
Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.
The effect of Raloxifene treatment in postmenopausal women with chronic kidney disease
The osteoporosis drug raloxifene increases bone mineral density and reduces the risk of vertebral fractures among postmenopausal women with mild to moderate chronic kidney disease (CKD), according to a study appearing in the July 2008 issue of the Journal of the American Society Nephrology.
Blue Dogs: We have agreement with House Dems on health bill
Work on the House health care reform bill is slowing as Rep. Henry Waxman of California and fiscally conservative Blue Dog Democrats have come to an agreement on Medicare payments, The New York Times reports.
BD Saf-T-Intima Safety Integrated IV Catheter System gets European approval for subcutaneous infusion therapy
BD (Becton, Dickinson and Company), a leading global medical technology company, announces the approval of the BD Saf-T-Intima Safety Integrated IV Catheter System for use in subcutaneous infusion therapies in Europe.
› Verified 1 days ago